Nesiritide
drugOn this page
Also known as Bnp-32Brain natriuretic peptide 32C01DX19NatrecorNesiritidaNesiritide recombinant
Summary
Nesiritide (CHEMBL1201668) is an approved protein (ATC C01DX19) targeting NPR1; indicated across 18 conditions including cardiovascular disorder and heart failure.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: C01DX19
- Targets: 1 (NPR1)
- Indications: 18 conditions
- Clinical trials: 50
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201668 |
| Name | Nesiritide |
| Type | Protein |
| Max phase | 4 |
| ATC | C01DX19 |
Also known as: Bnp-32, Brain natriuretic peptide 32, C01DX19, Natrecor, Nesiritida, Nesiritide, Nesiritide recombinant, NESIRITIDE
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| NPR1 | Guanylyl cyclase-A | Binding | 0.3% | P16066 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): NPR1.
Top Reactome pathways
3 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Muscle contraction | 1 | NPR1 |
| Cardiac conduction | 1 | NPR1 |
| Physiological factors | 1 | NPR1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| cGMP biosynthetic process | 1 |
| cell surface receptor signaling pathway | 1 |
| receptor guanylyl cyclase signaling pathway | 1 |
| body fluid secretion | 1 |
| regulation of blood pressure | 1 |
| obsolete positive regulation of cGMP-mediated signaling | 1 |
| negative regulation of angiogenesis | 1 |
| obsolete cGMP-mediated signaling | 1 |
| negative regulation of cell growth | 1 |
| positive regulation of urine volume | 1 |
| positive regulation of renal sodium excretion | 1 |
| dopamine metabolic process | 1 |
| regulation of vascular permeability | 1 |
| negative regulation of smooth muscle cell proliferation | 1 |
| blood vessel diameter maintenance | 1 |
Indications & clinical
Indications
18 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| heart failure | 3 | MONDO:0005252 | EFO:0003144 |
| congestive heart failure | 3 | MONDO:0005009 | EFO:0000373 |
| acute kidney injury | 3 | MONDO:0002492 | HP:0001919 |
| cardiomyopathy | 3 | MONDO:0004994 | EFO:0000318 |
| kidney disorder | 3 | MONDO:0005240 | EFO:0003086 |
| acute coronary syndrome | 3 | MONDO:0005542 | EFO:0005672 |
| myocardial infarction | 2 | MONDO:0005068 | EFO:0000612 |
| kidney failure | 2 | MONDO:0001106 | EFO:1002048 |
| congenital heart disease | 2 | MONDO:0005453 | HP:0030680 |
| acute myocardial infarction | 2 | MONDO:0004781 | EFO:0008583 |
| hypertensive disorder | 1 | MONDO:0005044 | EFO:0000537 |
| melanoma | 1 | MONDO:0005105 | EFO:0000756 |
| diabetes mellitus | 1 | MONDO:0005015 | EFO:0000400 |
| skin disorder | 1 | MONDO:0005093 | EFO:0000701 |
| obesity disorder | 0 | MONDO:0011122 | EFO:0001073 |
| hyperinsulinism | 0 | MONDO:0002177 | HP:0000842 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 50.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 12 |
| PHASE4 | 10 |
| PHASE2 | 10 |
| Not specified | 8 |
| PHASE1/PHASE2 | 7 |
| PHASE1 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00075179 | PHASE4 | TERMINATED | Natrecor in Pulmonary Hypertension |
| NCT00083772 | PHASE4 | TERMINATED | Use of Nesiritide in the Management of Acute Diastolic Heart Failure |
| NCT00186329 | PHASE4 | COMPLETED | BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS) |
| NCT00205426 | PHASE4 | COMPLETED | Natrecor for Pulmonary Hypertension in Lung Transplants |
| NCT00270829 | PHASE4 | TERMINATED | Renal Effects of Intrarenal Nesiritide |
| NCT00453453 | PHASE4 | TERMINATED | BNP Therapy Observation Unit Outcomes STudy (BOOST) |
| NCT00505791 | PHASE4 | WITHDRAWN | Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF |
| NCT00652652 | PHASE4 | COMPLETED | Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS |
| NCT00842023 | PHASE4 | COMPLETED | Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy |
| NCT01836809 | PHASE4 | TERMINATED | Nesiritide and Renal Function After the Total Artificial Heart |
| NCT00110201 | PHASE3 | UNKNOWN | The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure |
| NCT00170183 | PHASE3 | COMPLETED | Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure |
| NCT00270361 | PHASE3 | COMPLETED | FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization. |
| NCT00270374 | PHASE3 | COMPLETED | A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure. |
| NCT00270387 | PHASE3 | COMPLETED | A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy |
| NCT00270400 | PHASE3 | COMPLETED | A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure |
| NCT00271557 | PHASE3 | COMPLETED | A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels |
| NCT00288730 | PHASE3 | COMPLETED | A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest |
| NCT00475852 | PHASE3 | COMPLETED | A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure |
| NCT00530361 | PHASE3 | WITHDRAWN | An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine) |
| NCT00562692 | PHASE3 | TERMINATED | Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease |
| NCT00813202 | PHASE3 | COMPLETED | An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure |
| NCT02608996 | PHASE1/PHASE2 | RECRUITING | Nesiritide in Hypertension |
| NCT00091520 | PHASE2 | COMPLETED | A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure |
| NCT00119691 | PHASE2 | COMPLETED | Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction |
| NCT00145873 | PHASE2 | TERMINATED | Nesiritide in Chronic Heart Failure |
| NCT00240084 | PHASE2 | COMPLETED | Nesiritide and Vo2 Max in Heart Failure Patients |
| NCT00281671 | PHASE1/PHASE2 | TERMINATED | Nesiritide Use Following Cardiac Surgery in Infants |
| NCT00348556 | PHASE1/PHASE2 | TERMINATED | Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure |
| NCT00387621 | PHASE1/PHASE2 | COMPLETED | Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction |
| NCT00405639 | PHASE1/PHASE2 | COMPLETED | Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function |
| NCT00490724 | PHASE2 | COMPLETED | An Exploratory Study of Nesiritide in Participants With Acute Heart Failure |
| NCT00543309 | PHASE2 | TERMINATED | Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery |
| NCT00573144 | PHASE2 | COMPLETED | Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction |
| NCT00653042 | PHASE2 | COMPLETED | Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA |
| NCT01132846 | PHASE2 | COMPLETED | Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study |
| NCT01440881 | PHASE2 | COMPLETED | Does Nesiritide Provide Renal Protection |
| NCT01514357 | PHASE1/PHASE2 | TERMINATED | Nesiritide in Resistant Hypertension |
| NCT01544998 | PHASE1/PHASE2 | COMPLETED | Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure |
| NCT00818701 | PHASE1 | TERMINATED | Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1 molecules share ≥1 primary target. Top 1 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CARPERITIDE | ChEMBL | Phase 3 | NPR1 |